Perfromance Wealth Partners LLC Has $2.12 Million Holdings in Abbott Laboratories $ABT

Perfromance Wealth Partners LLC raised its position in Abbott Laboratories (NYSE:ABT) by 98.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,934 shares of the healthcare product maker’s stock after purchasing an additional 8,421 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in Abbott Laboratories were worth $2,122,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $31,000. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, February 4th. The stock was acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $101.77 on Wednesday. The stock has a market capitalization of $177.25 billion, a price-to-earnings ratio of 27.36, a PEG ratio of 1.64 and a beta of 0.79. The business has a 50-day moving average of $109.22 and a 200-day moving average of $120.47. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a fifty-two week low of $100.88 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Royal Bank Of Canada dropped their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Leerink Partners decreased their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Argus decreased their price objective on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Evercore decreased their price objective on Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating for the company in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $135.47.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.